Hongyang Shu

Hongyang Shu

Auto-generated profile, based on publicly available information

Hongyang Shu

Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, China; Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiologic Disorders, Huazhong University of Science and Technology, Wuhan, 430000, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
NLNa Li
Na Li
WHWeijian Hang
Weijian Hang
HSHongyang Shu
Hongyang Shu
NZNing Zhou
Ning Zhou
Cardiac fibrosis critically injured the cardiac structure and function of the hypertensive patients. However, the anti‐fibrotic strategy is still far from satisfaction. This study aims to determine the effect and mechanism of Pirfenidone (PFD), an anti‐lung fibrosis medicine, in the treatment of cardiac fibrosis and heart failure induced by pressure overload. Male C57BL/6 mice were subjected to thoracic aorta constriction (TAC) or sham surgery with the vehicle, PFD (300 mg/kg/day) or Captopril (CAP, 20 mg/kg/day). After 8 weeks of surgery, mice were tested by echocardiography, and then sacrificed followed by morphological and molecular biological analysis. Compared to the sham mice, TAC mice showed a remarkable cardiac hypertrophy, interstitial and perivascular fibrosis and resultant heart failure, which were reversed by PFD and CAP significantly. The enhanced cardiac expression of TGF‐β1 and phosphorylation of Smad3 in TAC mice were both restrained by PFD. Cardiac fibroblasts isolated from adult C57BL/6 mice were treated by Angiotensin II, which led to significant increases in cellular proliferation and levels of α‐SMA, vimentin, TGF‐β1 and phosphorylated TGF‐β receptor and Smad3. These changes were markedly inhibited by pre‐treatment of PFD. Collectively, PFD attenuates myocardial fibrosis and dysfunction induced by pressure overload via inhibiting the activation of TGF‐β1/Smad3 signalling pathway.

13 January 2021 in Biochemical Society Transactions
Verified
Journal Article
Open access
PDF file
HSHongyang Shu
Hongyang Shu
YPYizhong Peng
Yizhong Peng
WHWeijian Hang
Weijian Hang
NZNing Zhou
Ning Zhou
DWDao Wen Wang
Dao Wen Wang
Valosin-containing protein (VCP/p97) is a member of the conserved type II AAA+ (ATPases associated with diverse cellular activities) family of proteins with multiple biological functions, especially in protein homeostasis. Mutations in VCP/p97 are reportedly related to unique autosomal dominant diseases, which may worsen cardiac function. Although the structure of VCP/p97 has been clearly characterized, with reports of high abundance in the heart, research focusing on the molecular mechanisms underpinning the roles of VCP/p97 in the cardiovascular system has been recently undertaken over the past decades. Recent studies have shown that VCP/p97 deficiency affects myocardial fibers and induces heart failure, while overexpression of VCP/p97 eliminates ischemia/reperfusion injury and relieves pathological cardiac hypertrophy caused by cardiac pressure overload, which is related to changes in the mitochondria and calcium overload. However, certain studies have drawn opposing conclusions, including the mitigation of ischemia/reperfusion injury via inhibition of VCP/p97 ATPase activity. Nevertheless, these emerging studies shed light on the role of VCP/p97 and its therapeutic potential in cardiovascular diseases. In other words, VCP/p97 may be involved in the development of cardiovascular disease, and is anticipated to be a new therapeutic target. This review summarizes current findings regarding VCP/p97 in the cardiovascular system for the first time, and discusses the role of VCP/p97 in cardiovascular disease.

20 April 2026 in Atherosclerosis
Verified
Journal Article
Open access
RLRuolin Lyu
Ruolin Lyu
ZHZiyi He
Ziyi He
NLNa Li
Na Li
ZZZixuan Zhang
Zixuan Zhang
DWDao Wen Wang
Dao Wen Wang
HSHongyang Shu
Hongyang Shu
Vascular smooth muscle cell (VSMC)-derived foam cells critically drive atherosclerotic plaque progression, yet their regulatory mechanisms remain incompletely understood. This study aimed to elucidate the pathophysiological role of the VSMC-enriched factor axin interactor, dorsalization-associated (AIDA) in this process and evaluate its therapeutic potential. We utilized VSMC-specific AIDA knockout in male ApoE-/- mice and adenoviral shRNA silencing in oxLDL-stimulated murine aortic vascular smooth muscle cells (MOVAS), combined with co-immunoprecipitation (Co-IP), cholesterol flux assays, and ubiquitination profiling, which revealed that AIDA is selectively upregulated in VSMCs within human and murine atherosclerotic plaques. AIDA knockout attenuated aortic plaque burden, fibrosis, and elastic fiber fragmentation in vivo, and suppressed oxidized low-density lipoprotein (oxLDL) uptake and foam cell formation in vitro by specifically impairing CD36 membrane trafficking without affecting cholesterol efflux. Mechanistically, AIDA scaffolds HMG-CoA reductase degradation protein 1 (HRD1)-mediated K63-linked ubiquitination of vesicle-associated membrane protein 3 (VAMP3), resulting in the VAMP3-CD36 interaction and subsequent CD36 membrane translocation. These results demonstrate that AIDA promotes VSMC-derived foam cell formation by facilitating CD36 trafficking through the HRD1-VAMP3 ubiquitination axis, identifying the AIDA-HRD1-VAMP3-CD36 pathway as a potential novel strategy for the treatment of atherosclerosis.

9 November 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NZN Zhou
N Zhou
JCJ Cheng
J Cheng
LQL Qiu
L Qiu
ZZZ X Zhang
Z X Zhang
NLNailin Li
Nailin Li
ZXZhi Cheng Xiao
Zhi Cheng Xiao
Background and objective: Nicorandil and beta-adrenergic receptor blockers (BBs) are commonly used anti-anginal drugs. However, the effect of combined nicorandil and BBs compared with that of BBs alone on long-term clinical outcomes in patients with coronary heart disease (CHD) remains undetermined. Accordingly, a real-world observational study was performed to assess the long-term potential of nicorandil combined with BBs in Chinese patients with CHD. Methods: A multicenter retrospective cohort study involving two tertiary healthcare institutions in our city was performed. Adult patients who had been hospitalized for CHD and treated for angina with a combination of nicorandil and BBs or BBs alone between August 2002 and March 2020 were included. The effect of different treatments on the cumulative incidence of major adverse cardiovascular events (MACE) and their components (myocardial infarction [MI], stroke, and all-cause mortality) within a follow-up duration of 2.5 years were analyzed using Kaplan–Meier survival curves. An inverse probability of treatment weighting (IPTW) method was used to adjust for the possible effect of confounding factors. The hazard ratio (HR) and corresponding 95% confidence interval (CI) were calculated using a Cox regression analysis. Sensitivity analyses based on IPTW with trimming or limited to patients admitted after January 1, 2012, were performed to evaluate the robustness of the findings. Results: Overall, 4,669 patients receiving the combined treatment and 12,243 receiving BBs alone were included. After IPTW, the results demonstrated that the combined treatment was associated with a significantly reduced incidence of MACE (HR 0.80, 95% CI: 0.73–0.87, P < 0.0001)(Figure 1) and stroke (HR 0.48, 95% CI 0.42–0.54) but not of MI (HR 1.03, 95% CI 0.92–1.15) or all-cause mortality (HR 0.93, 95% CI 0.64–1.37). Interaction analyses were performed for the following subgroups: age (younger than 65 or is and older than 65 years), gender, acute coronary syndrome (ACS), smoking, drinking, revascularization, diabetes and hypertension, and showed a favorable consistency with the primary outcome (Figure 2). Conclusion: A combined anti-angina treatment of nicorandil and BBs may be more effective than a treatment of BBs alone in reducing the long-term incidence of MACE in patients with CHD.The Kaplan-Meier curves of the outcomesThe forest plot of the subgroup analysis

29 June 2021 in Research Square
Verified
Preprint
Open access
PDF file
NZNing Zhou
Ning Zhou
HSHongyang Shu
Hongyang Shu
WHWeijian Hang
Weijian Hang
CLChenze Li
Chenze Li
DWDongyang Wu
Dongyang Wu
DWDao Wen Wang
Dao Wen Wang
A life support-based comprehensive treatment regimen, in which an intra-aortic balloon pump (IABP) unloads the left ventricle, has reduced the mortality of patients with fulminant myocarditis (FM). This study evaluated the efficacy of IABP in the treatment of patients with FM. A total of 100 patients diagnosed with FM were divided into two groups depending on the application of IABPs. 57 (57%) received IABPs within 30 min after admission (IABP group), whereas 43 (43%) did not (non-IABP group). In IABP group, 24.6% (14/57) died, compared to 34.9% (15/43) of those without IABPs (P < 0.01). The mean blood pressure (MBP), averaged heart rate (AHR), and left ventricular ejection fraction (LVEF) were similar between the two groups on admission. However, compared to the non-IABP group, MBP and LVEF were increased and AHR was significantly in IABP group. IABPs reduced the in-hospital mortality risk and improved the cardiac dysfunction in patients with FM.